CRISPR Therapeutics AG (CRSP)

CRISPR Therapeutics AG Stock Forecast

Stock Price Forecast

The 15 analysts with 12-month price forecasts for CRISPR Therapeutics AG stock have an average target of 74.53, with a low estimate of 32 and a high estimate of 120. The average target predicts an increase of 98.27% from the current stock price of 37.59.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$32	$74.53	$82	$120
Change	-14.87%	+98.27%	+118.14%	+219.23%

Analyst Ratings

The average analyst rating for CRISPR Therapeutics AG stock from 17 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25	May '25
Strong Buy	5	6	7	7	6	6
Buy	3	3	4	4	4	4
Hold	9	9	9	9	8	6
Sell	1	1	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	18	19	21	21	19	17

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Gena Wang Barclays	Barclays	Hold Maintains $56 → $42	Hold	Maintains	$56 → $42	+11.73%	May 9, 2025
Salveen Richter Goldman Sachs	Goldman Sachs	Hold Maintains $53 → $47	Hold	Maintains	$53 → $47	+25.03%	May 8, 2025
Gil Blum Needham	Needham	Strong Buy Maintains $84 → $81	Strong Buy	Maintains	$84 → $81	+115.48%	May 7, 2025
Geulah Livshits Chardan Capital	Chardan Capital	Strong Buy Maintains $84 → $82	Strong Buy	Maintains	$84 → $82	+118.14%	May 7, 2025
Gil Blum Needham	Needham	Strong Buy Reiterates $84	Strong Buy	Reiterates	$84	+123.46%	Apr 9, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

56.47M

Increased by 51.35%

from 37.31M

Revenue Next Year

215.82M

Increased by 282.16%

from 56.47M

EPS This Year

-5.03

from -4.34

EPS Next Year

-4.19

from -5.03

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	719.00K	914.96M	1.20M	371.21M	37.31M	56.47M	215.82M	486.23M
Revenue Growth	-99.75%	127,154.94%	-99.87%	30,885.48%	-89.95%	51.35%	282.16%	125.29%
EPS	-5.29	4.70	-8.36	-1.94	-4.34	-5.03	-4.19	-2.80
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	30	26	15

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	164.9M	1.6B	2.4B
Avg	56.5M	215.8M	486.2M
Low	n/a	n/a	88.2M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	341.8%	2,651.8%	1,002.8%
Avg	51.3%	282.2%	125.3%
Low	-	-	-59.1%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-3.51	4.15	5.79
Avg	-5.03	-4.19	-2.80
Low	-6.77	-7.54	-7.61

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.